Obesity Medicine最新文献

英文中文

Survey on the herbal combinations in traditional Vietnamese medicine formulas for obesity treatment based on literature

Q2 Medicine

Obesity Medicine

Pub Date : 2025-03-01 DOI: 10.1016/j.obmed.2025.100598

Duong Thi Huong Nguyen, Huy Khanh Tang, An Thi Hoai Nguyen, Luu Bao Le

Objectives

Today, obesity is a significant public health concern. Traditional medicine, known for its minimal side effects and positive outcomes, is increasingly being utilized as an alternative intervention in clinical practice. This study seeks to examine Vietnamese literature to identify herbs that can aid in reducing obesity and to interpret the association rules among these herbs.

Methods

Four hundred thirty-six formulas were collected from 43 documents suited to inclusion criteria. Using Microsoft Excel 2016, we continuously interpreted the characteristics of 320 herbs extracted from 436 anti-obesity formulas. The Apriori algorithm, operated by R Studio version 4.3.3, investigated the association rules among core materials.

Results

Shan Zha (Fructus crataegi) is the most popular herb mentioned in 436 compounded medications. The predominant property and flavor were warm (33,02%) and sweet (52,7%), respectively. Eventually, we also found 18 association rules and screened out 7 potential anti-obesity herbs. Each rule consists of two or three components. Especially, the greatest prevalent associated law is a triple combination among Fu Ling (Poria cocos), Ban Xia (Rhizoma pinelliae), and Chen Pi (Pericarpium citri reticulatae).

Conclusions

This study documents traditional Vietnamese medicinal knowledge on herbs with anti-obesity properties. According to the traditional function, all of herbs can be divided into these classifications: Tonify Spleen-Qi, Move Qi and invigorate Blood, Resolve retention of food, Resolve Dampness and Promoting diuresis. Besides, the pharmacological functions of them are suppressing appetite, inhibition of fat absorption and elevation of fat metabolism rate.

{"title":"Survey on the herbal combinations in traditional Vietnamese medicine formulas for obesity treatment based on literature","authors":"Duong Thi Huong Nguyen, Huy Khanh Tang, An Thi Hoai Nguyen, Luu Bao Le","doi":"10.1016/j.obmed.2025.100598","DOIUrl":"10.1016/j.obmed.2025.100598","url":null,"abstract":"<div><h3>Objectives</h3><div>Today, obesity is a significant public health concern. Traditional medicine, known for its minimal side effects and positive outcomes, is increasingly being utilized as an alternative intervention in clinical practice. This study seeks to examine Vietnamese literature to identify herbs that can aid in reducing obesity and to interpret the association rules among these herbs.</div></div><div><h3>Methods</h3><div>Four hundred thirty-six formulas were collected from 43 documents suited to inclusion criteria. Using Microsoft Excel 2016, we continuously interpreted the characteristics of 320 herbs extracted from 436 anti-obesity formulas. The Apriori algorithm, operated by R Studio version 4.3.3, investigated the association rules among core materials.</div></div><div><h3>Results</h3><div>Shan Zha (<em>Fructus crataegi</em>) is the most popular herb mentioned in 436 compounded medications. The predominant property and flavor were warm (33,02%) and sweet (52,7%), respectively. Eventually, we also found 18 association rules and screened out 7 potential anti-obesity herbs. Each rule consists of two or three components. Especially, the greatest prevalent associated law is a triple combination among Fu Ling (<em>Poria cocos</em>)<em>,</em> Ban Xia (<em>Rhizoma pinelliae</em>)<em>,</em> and Chen Pi (<em>Pericarpium citri reticulatae</em>).</div></div><div><h3>Conclusions</h3><div>This study documents traditional Vietnamese medicinal knowledge on herbs with anti-obesity properties. According to the traditional function, all of herbs can be divided into these classifications: Tonify Spleen-Qi, Move Qi and invigorate Blood, Resolve retention of food, Resolve Dampness and Promoting diuresis. Besides, the pharmacological functions of them are suppressing appetite, inhibition of fat absorption and elevation of fat metabolism rate.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100598"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Healing wounds in diabetes: Exploring cutting-edge natural extracellular vesicle therapeutics

Q2 Medicine

Obesity Medicine

Pub Date : 2025-02-21 DOI: 10.1016/j.obmed.2025.100597

Mumtaj Bano Miya , Pankaj Chaturvedi , Vandana Pathak , Prakash Chandra Gupta , Anuradha Kalani

Managing diabetes-related foot ulcers is challenging due to their slow healing process, peripheral neuropathy, reduced blood flow and increased risk of infection. Exploring alternative approaches, such as medicinal plant-based therapies, could provide promising solutions for diabetic wound healing. The current review discusses the therapeutic potential of different extracellular vesicles for diabetic wound healing. A newly developed oxygenated nanotherapeutic, OXY-Exo^Aloe, is further discussed, which is formulated by combining the medicinal potential of Aloe barbadensis, Azadirachta indica, and Zingiber officinale. The oxygenated nanotherapeutics could offer a multi-faceted approach to wound healing and may revolutionize advancements in nanotechnology and medicinal plant-based therapies for the treatment of diabetic foot ulcers in the future.

引用次数: 0

Association and inequality between socioeconomic status and the prevalence of overweight and obesity among adults aged 18 and older in Bangladesh

Q2 Medicine

Obesity Medicine

Pub Date : 2025-02-19 DOI: 10.1016/j.obmed.2025.100595

Sukanta Das

Background

Overweight and obesity have emerged as significant public health concerns in Bangladesh. This study aims to assess the association between socioeconomic status (SES) and the prevalence of overweight and obesity while identifying socioeconomic inequalities among adults aged 18 and older in Bangladesh.

Methods

Using data from the Bangladesh Demographic and Health Survey (BDHS) 2017–18, this study analyzed a sample of 24,478 adults. Overweight and obesity were classified according to the World Health Organization's Body Mass Index (BMI) guidelines. SES was measured by wealth index, and its association with overweight and obesity was examined using multivariate logistic regression analysis. Socioeconomic inequality was evaluated using concentration curves and indexes.

Results

The overall prevalence of overweight and obesity was 31.8% and 13.4%, respectively. Even after controlling for age, gender, education, and place of residence, higher socioeconomic status was significantly associated with an increased risk of being overweight or obese. Adults in the richest wealth category were 3.2 times more likely to be overweight and 9.8 times more likely to be obese compared to those in the poorest category (p < 0.01). The concentration index of 0.35 (CI: 0.33 to 0.37;

p

< 0.01) indicated that overweight and obesity were more prevalent among wealthier adults, highlighting a pro-rich inequality.

Conclusion

There is a significant socioeconomic disparity in the prevalence of overweight and obesity in Bangladesh, with wealthier adults disproportionately affected. Targeted public health initiatives are needed to curb this growing epidemic, particularly among wealthier groups, to reduce obesity-related non-communicable diseases.

{"title":"Association and inequality between socioeconomic status and the prevalence of overweight and obesity among adults aged 18 and older in Bangladesh","authors":"Sukanta Das","doi":"10.1016/j.obmed.2025.100595","DOIUrl":"10.1016/j.obmed.2025.100595","url":null,"abstract":"<div><h3>Background</h3><div>Overweight and obesity have emerged as significant public health concerns in Bangladesh. This study aims to assess the association between socioeconomic status (SES) and the prevalence of overweight and obesity while identifying socioeconomic inequalities among adults aged 18 and older in Bangladesh.</div></div><div><h3>Methods</h3><div>Using data from the Bangladesh Demographic and Health Survey (BDHS) 2017–18, this study analyzed a sample of 24,478 adults. Overweight and obesity were classified according to the World Health Organization's Body Mass Index (BMI) guidelines. SES was measured by wealth index, and its association with overweight and obesity was examined using multivariate logistic regression analysis. Socioeconomic inequality was evaluated using concentration curves and indexes.</div></div><div><h3>Results</h3><div>The overall prevalence of overweight and obesity was 31.8% and 13.4%, respectively. Even after controlling for age, gender, education, and place of residence, higher socioeconomic status was significantly associated with an increased risk of being overweight or obese. Adults in the richest wealth category were 3.2 times more likely to be overweight and 9.8 times more likely to be obese compared to those in the poorest category (p < 0.01). The concentration index of 0.35 (CI: 0.33 to 0.37; <span><math><mrow><mi>p</mi></mrow></math></span> < 0.01) indicated that overweight and obesity were more prevalent among wealthier adults, highlighting a pro-rich inequality.</div></div><div><h3>Conclusion</h3><div>There is a significant socioeconomic disparity in the prevalence of overweight and obesity in Bangladesh, with wealthier adults disproportionately affected. Targeted public health initiatives are needed to curb this growing epidemic, particularly among wealthier groups, to reduce obesity-related non-communicable diseases.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100595"},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143465126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correlation between estimated glucose disposal rate, carotid intima-media thickness and cardiovascular risk prediction scales in adolescents and young adults with type 1 diabetes

Q2 Medicine

Obesity Medicine

Pub Date : 2025-02-18 DOI: 10.1016/j.obmed.2025.100592

David Sánchez-García, Eloísa Saavedra-Castillo, Mariela Rivas-Hernández, Luis Diego Maximiliano Ramos-Anthony, Graciela Gómez-Martínez, Marcelo Diaz-Sallas, Dania Lizet Quintanilla-Flores

Aims

To analyze the correlation between estimated glucose disposal rate (eGDR), Carotid intima-media thickness (CIMT) and cardiovascular risk prediction scales in young adults with diabetes type 1 (T1D).

Methods

A cross-sectional, analytical, and retrospective study was conducted. Patients with T1D > 15 years were included, insulin resistance (IR) was defined by eGDR <8 mg/kg/min, and preclinical atherosclerosis as ≥0.54 mm of CIMT, STENO and ESC cardiovascular risk was calculated. Pearson's correlation test was used to measure the strength of association between them.

Results

102 patients with a median age of 19 years, HbA1c of 8.2%, diabetes duration of 8 years were included. IR was found in 50.9% of the patients and preclinical atherosclerosis in 46.1%, with a median CIMT of 0.52 mm. An inverse correlation was obtained between the eGDR and CIMT r = −0.23, p = 0.021, and STENO r = 0.33, p=<0.001, CIMT was higher in the IR group 0.54 vs 0.50 mm, p = 0.047, also was associated with more microvascular complications 36.5% vs 18%, p = 0.03, and proinflammatory markers, p=<0.001.

Conclusions

Carotid intima-media thickening is inversely associated with insulin sensitivity, the eGDR value could be used as a cardiovascular and as a enhance risk factor and could help to decide treatment in patients whit T1D.

{"title":"Correlation between estimated glucose disposal rate, carotid intima-media thickness and cardiovascular risk prediction scales in adolescents and young adults with type 1 diabetes","authors":"David Sánchez-García, Eloísa Saavedra-Castillo, Mariela Rivas-Hernández, Luis Diego Maximiliano Ramos-Anthony, Graciela Gómez-Martínez, Marcelo Diaz-Sallas, Dania Lizet Quintanilla-Flores","doi":"10.1016/j.obmed.2025.100592","DOIUrl":"10.1016/j.obmed.2025.100592","url":null,"abstract":"<div><h3>Aims</h3><div>To analyze the correlation between estimated glucose disposal rate (eGDR), Carotid intima-media thickness (CIMT) and cardiovascular risk prediction scales in young adults with diabetes type 1 (T1D).</div></div><div><h3>Methods</h3><div>A cross-sectional, analytical, and retrospective study was conducted. Patients with T1D > 15 years were included, insulin resistance (IR) was defined by eGDR <8 mg/kg/min, and preclinical atherosclerosis as ≥0.54 mm of CIMT, STENO and ESC cardiovascular risk was calculated. Pearson's correlation test was used to measure the strength of association between them.</div></div><div><h3>Results</h3><div>102 patients with a median age of 19 years, HbA1c of 8.2%, diabetes duration of 8 years were included. IR was found in 50.9% of the patients and preclinical atherosclerosis in 46.1%, with a median CIMT of 0.52 mm. An inverse correlation was obtained between the eGDR and CIMT r = −0.23, p = 0.021, and STENO r = 0.33, p=<0.001, CIMT was higher in the IR group 0.54 vs 0.50 mm, p = 0.047, also was associated with more microvascular complications 36.5% vs 18%, p = 0.03, and proinflammatory markers, p=<0.001.</div></div><div><h3>Conclusions</h3><div>Carotid intima-media thickening is inversely associated with insulin sensitivity, the eGDR value could be used as a cardiovascular and as a enhance risk factor and could help to decide treatment in patients whit T1D.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100592"},"PeriodicalIF":0.0,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143471572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Murraya koenigii Linn. Modulate diabetic neuropathy via attenuation of mechanical hyperalgesia and allodynia in STZ-induced diabetic rats

Q2 Medicine

Obesity Medicine

Pub Date : 2025-02-17 DOI: 10.1016/j.obmed.2025.100593

Randhir Singh , Shah Asma Farooq , Ashi Mannan , Nikhil Garg , Sushma Devi , Kamal Dua , Thakur Gurjeet Singh

Introduction

The present research aims to examine the efficacy of Murraya koenigii (L.) extracts in the management of diabetic peripheral neuropathy (DPN).

Methods

A dose of 65 mg/kg of streptozotocin (STZ) was administered intraperitoneally (i.p.) in fresh citrate buffer with a pH of 4.5 to induce diabetes 15 min after nicotinamide (230 mg/kg, ip) was administered and on 60th day development of DPN was evaluated by measuring behavioural parameters like tactile allodynia and hyperalgesia. In-vitro and in-vivo techniques were employed for estimation of oxidative stress.

Results

Oral administration of extracts at various doses as well as standard drug was continued up to 90th day after 60th day of STZ-NAD administration. In diabetic animals, antioxidants like as SOD and GSH levels was reduced while the level of TBARS, nitrites, TNF-α, and AGE production were significantly increased. These extracts were discovered to positively impact fasting blood sugar levels, food intake, and body weight loss management. Furthermore, research demonstrated that the extracts had positive impact on pain perception as measured by thermal and mechanical hyperalgesia in experimental rats. Studies of these extracts, both in-vivo and in-vitro, indicated their potential to reduce oxidative stress as well as hyperglycemia, which are crucial in the progression of diabetes complications.

Conclusion

It can be concluded that Murraya koenigii (L.) leaf extracts, ameliorates diabetes and diabetic peripheral neuropathy by regulating hyperglycemia and oxidative stress.

{"title":"Murraya koenigii Linn. Modulate diabetic neuropathy via attenuation of mechanical hyperalgesia and allodynia in STZ-induced diabetic rats","authors":"Randhir Singh , Shah Asma Farooq , Ashi Mannan , Nikhil Garg , Sushma Devi , Kamal Dua , Thakur Gurjeet Singh","doi":"10.1016/j.obmed.2025.100593","DOIUrl":"10.1016/j.obmed.2025.100593","url":null,"abstract":"<div><h3>Introduction</h3><div>The present research aims to examine the efficacy of <em>Murraya koenigii</em> (L.) extracts in the management of diabetic peripheral neuropathy (DPN).</div></div><div><h3>Methods</h3><div>A dose of 65 mg/kg of streptozotocin (STZ) was administered intraperitoneally (i.p.) in fresh citrate buffer with a pH of 4.5 to induce diabetes 15 min after nicotinamide (230 mg/kg, ip) was administered and on 60th day development of DPN was evaluated by measuring behavioural parameters like tactile allodynia and hyperalgesia. <em>In-vitro</em> and <em>in-vivo</em> techniques were employed for estimation of oxidative stress.</div></div><div><h3>Results</h3><div>Oral administration of extracts at various doses as well as standard drug was continued up to 90th day after 60th day of STZ-NAD administration. In diabetic animals, antioxidants like as SOD and GSH levels was reduced while the level of TBARS, nitrites, TNF-α, and AGE production were significantly increased. These extracts were discovered to positively impact fasting blood sugar levels, food intake, and body weight loss management. Furthermore, research demonstrated that the extracts had positive impact on pain perception as measured by thermal and mechanical hyperalgesia in experimental rats. Studies of these extracts, both <em>in-vivo</em> and <em>in-vitro,</em> indicated their potential to reduce oxidative stress as well as hyperglycemia, which are crucial in the progression of diabetes complications.</div></div><div><h3>Conclusion</h3><div>It can be concluded that <em>Murraya koenigii</em> (L.) leaf extracts, ameliorates diabetes and diabetic peripheral neuropathy by regulating hyperglycemia and oxidative stress.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100593"},"PeriodicalIF":0.0,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143479488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GLP-1 agonists in Type 1 diabetes – Indications and use

Q2 Medicine

Obesity Medicine

Pub Date : 2025-02-11 DOI: 10.1016/j.obmed.2025.100591

Panadeekarn Panjawatanan, Richard J. Comi

Objective

Insulin therapy in Type 1 diabetes is associated with weight gain. Glucagon-like peptide 1 (GLP-1) agonists, which lower blood glucose and promote weight loss, may help reverse this trend and reduce hemoglobin A1C (A1C) levels.

Methods

Patients with Type 1 diabetes with concomitant GLP-1 agonists used for at least one year were included. Observed outcomes were the change in A1C, weight, and basal insulin use compared at baseline and 12 months using mixed models repeated measures.

Results

Forty-nine patients with weight gain were included. Prior to treatment, patients gained an average of 2.0 kg annually over three years. After 12 months of GLP-1 agonist therapy, weight significantly decreased from 97.6 kg (95% CI: 92.7–102.5) to 90.0 kg (95% CI: 84.9–95.1) (p < 0.001). A1C levels also improved significantly, from 8.2% (95% CI: 7.9–8.6) to 7.6% (95% CI: 7.2–7.9) (p < 0.001). Basal insulin requirements were significantly reduced.

Conclusion

We conclude that GLP-1 agonists effectively reverse the trend of weight gain and improve A1C levels in patients with Type 1 diabetes.

{"title":"GLP-1 agonists in Type 1 diabetes – Indications and use","authors":"Panadeekarn Panjawatanan, Richard J. Comi","doi":"10.1016/j.obmed.2025.100591","DOIUrl":"10.1016/j.obmed.2025.100591","url":null,"abstract":"<div><h3>Objective</h3><div>Insulin therapy in Type 1 diabetes is associated with weight gain. Glucagon-like peptide 1 (GLP-1) agonists, which lower blood glucose and promote weight loss, may help reverse this trend and reduce hemoglobin A1C (A1C) levels.</div></div><div><h3>Methods</h3><div>Patients with Type 1 diabetes with concomitant GLP-1 agonists used for at least one year were included. Observed outcomes were the change in A1C, weight, and basal insulin use compared at baseline and 12 months using mixed models repeated measures.</div></div><div><h3>Results</h3><div>Forty-nine patients with weight gain were included. Prior to treatment, patients gained an average of 2.0 kg annually over three years. After 12 months of GLP-1 agonist therapy, weight significantly decreased from 97.6 kg (95% CI: 92.7–102.5) to 90.0 kg (95% CI: 84.9–95.1) (p < 0.001). A1C levels also improved significantly, from 8.2% (95% CI: 7.9–8.6) to 7.6% (95% CI: 7.2–7.9) (p < 0.001). Basal insulin requirements were significantly reduced.</div></div><div><h3>Conclusion</h3><div>We conclude that GLP-1 agonists effectively reverse the trend of weight gain and improve A1C levels in patients with Type 1 diabetes.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100591"},"PeriodicalIF":0.0,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143420602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A novel therapeutic approach for hormonal imbalance in polycystic ovarian syndrome; evaluating the effects of Nutrition Bio-Shield Supplement in an animal model

Q2 Medicine

Obesity Medicine

Pub Date : 2025-02-08 DOI: 10.1016/j.obmed.2025.100590

Mehrdad Mosadegh , Yasaman Sadeghi , Aref Khalkhali , Yousef Erfani

Background

s: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that disrupts hormone balance, leading to infertility and metabolic issues. This study evaluates the effects of a novel nutritional supplement, Nutrition Bio-Shield (NBS), on hormonal regulation in a letrozole-induced PCOS rat model.

Methods

Twenty-five female Wistar rats were assigned to five groups: healthy control, PCOS control, and three groups treated with varying doses of NBS (12.5 mg/kg, 25 mg/kg, and 50 mg/kg). PCOS was induced using letrozole, and NBS was administered for 21 days. Serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, progesterone, and estradiol were measured using radioimmunoassay.

Results

NBS treatment significantly improved hormone levels compared to the PCOS control group. The highest dose (50 mg/kg) effectively reduced LH and testosterone while increasing progesterone and estradiol levels (p < 0.05), nearing those of the healthy controls. The 25 mg/kg dose also showed considerable improvement in hormone balance, whereas the 12.5 mg/kg dose had a moderate effect. FSH levels were notably reduced in both 50 mg/kg and 25 mg/kg groups, suggesting a dose-dependent response to NBS treatment.

Conclusion

NBS supplementation successfully ameliorated hormonal imbalances in a PCOS rat model, demonstrating its potential as a natural therapeutic option for managing PCOS. Further research is needed to confirm these effects in clinical settings.

{"title":"A novel therapeutic approach for hormonal imbalance in polycystic ovarian syndrome; evaluating the effects of Nutrition Bio-Shield Supplement in an animal model","authors":"Mehrdad Mosadegh , Yasaman Sadeghi , Aref Khalkhali , Yousef Erfani","doi":"10.1016/j.obmed.2025.100590","DOIUrl":"10.1016/j.obmed.2025.100590","url":null,"abstract":"<div><h3>Background</h3><div>s: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that disrupts hormone balance, leading to infertility and metabolic issues. This study evaluates the effects of a novel nutritional supplement, Nutrition Bio-Shield (NBS), on hormonal regulation in a letrozole-induced PCOS rat model.</div></div><div><h3>Methods</h3><div>Twenty-five female Wistar rats were assigned to five groups: healthy control, PCOS control, and three groups treated with varying doses of NBS (12.5 mg/kg, 25 mg/kg, and 50 mg/kg). PCOS was induced using letrozole, and NBS was administered for 21 days. Serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, progesterone, and estradiol were measured using radioimmunoassay.</div></div><div><h3>Results</h3><div>NBS treatment significantly improved hormone levels compared to the PCOS control group. The highest dose (50 mg/kg) effectively reduced LH and testosterone while increasing progesterone and estradiol levels (p < 0.05), nearing those of the healthy controls. The 25 mg/kg dose also showed considerable improvement in hormone balance, whereas the 12.5 mg/kg dose had a moderate effect. FSH levels were notably reduced in both 50 mg/kg and 25 mg/kg groups, suggesting a dose-dependent response to NBS treatment.</div></div><div><h3>Conclusion</h3><div>NBS supplementation successfully ameliorated hormonal imbalances in a PCOS rat model, demonstrating its potential as a natural therapeutic option for managing PCOS. Further research is needed to confirm these effects in clinical settings.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100590"},"PeriodicalIF":0.0,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143420603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative analysis of safoof-e− muhazzil and orlistat on obesity and markers of obesity

Q2 Medicine

Obesity Medicine

Pub Date : 2025-02-08 DOI: 10.1016/j.obmed.2025.100589

Mohd Aslam , Ahmad Faraz , Zaki Ahmad Siddiqui , Maaz Ozair , Hamid Ashraf , Abdul Mannan

Introduction

Obesity is truly a pandemic and associated with increased risk of multiple non-communicable diseases. The available pharmacotherapy of obesity is associated with multiple limitations. We have studied the effect of sufoof e muhazzil and compared it with orlistat in non-diabetic patients with obesity.

Material and methods

It was an open-label, interventional prospective study including 200 patients with obesity. These patients, aged between 18 and 60 years, had a body mass index (BMI) of 25–40 kg/m². We divided them equally between the Sufoof e Muhazzil and Orlistat groups. The dose of sufoof e muhazzil was 6 gm/day, and orlistat was 120 mg twice daily for 2 months. We assessed the effect on weight, BMI, biochemical, and inflammatory markers at the onset and at the end of the study.

Result

The mean age, weight, BMI, and waist circumference were 37.85 years and 35.71 years, 80.7 kg and 74.9 kg, 32.7 kg/m² and 32.4 kg/m², and 113.0 cm and 112.5 cm, respectively, for the orlistat and sufoof groups. There was a significant reduction in weight, BMI, and abdominal circumference in both groups (p value < 0.001 for all). Biochemical and inflammatory parameters also improved significantly in both groups. Sufoof e muhazzil use was associated with greater reductions in weight (5.8 vs 4.4 kg), BMI (2.5 vs 1.9 kg/m²) than orlistat.

Conclusion

Both orlistat and sufoof e muhazzil are associated with significant weight reduction and improvement in biochemical and inflammatory parameters. Both the drugs demonstrated excellent safety and tolerability.

{"title":"Comparative analysis of safoof-e− muhazzil and orlistat on obesity and markers of obesity","authors":"Mohd Aslam , Ahmad Faraz , Zaki Ahmad Siddiqui , Maaz Ozair , Hamid Ashraf , Abdul Mannan","doi":"10.1016/j.obmed.2025.100589","DOIUrl":"10.1016/j.obmed.2025.100589","url":null,"abstract":"<div><h3>Introduction</h3><div>Obesity is truly a pandemic and associated with increased risk of multiple non-communicable diseases. The available pharmacotherapy of obesity is associated with multiple limitations. We have studied the effect of sufoof e muhazzil and compared it with orlistat in non-diabetic patients with obesity.</div></div><div><h3>Material and methods</h3><div>It was an open-label, interventional prospective study including 200 patients with obesity. These patients, aged between 18 and 60 years, had a body mass index (BMI) of 25–40 kg/m<sup>2</sup>. We divided them equally between the Sufoof e Muhazzil and Orlistat groups. The dose of sufoof e muhazzil was 6 gm/day, and orlistat was 120 mg twice daily for 2 months. We assessed the effect on weight, BMI, biochemical, and inflammatory markers at the onset and at the end of the study.</div></div><div><h3>Result</h3><div>The mean age, weight, BMI, and waist circumference were 37.85 years and 35.71 years, 80.7 kg and 74.9 kg, 32.7 kg/m<sup>2</sup> and 32.4 kg/m<sup>2</sup>, and 113.0 cm and 112.5 cm, respectively, for the orlistat and sufoof groups. There was a significant reduction in weight, BMI, and abdominal circumference in both groups (p value < 0.001 for all). Biochemical and inflammatory parameters also improved significantly in both groups. Sufoof e muhazzil use was associated with greater reductions in weight (5.8 vs 4.4 kg), BMI (2.5 vs 1.9 kg/m<sup>2</sup>) than orlistat.</div></div><div><h3>Conclusion</h3><div>Both orlistat and sufoof e muhazzil are associated with significant weight reduction and improvement in biochemical and inflammatory parameters. Both the drugs demonstrated excellent safety and tolerability.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100589"},"PeriodicalIF":0.0,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143379000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obesity-driven hunger: From pathophysiology to intervention

Q2 Medicine

Obesity Medicine

Pub Date : 2025-02-05 DOI: 10.1016/j.obmed.2025.100588

Ahmad Khusairi Azemi , Yahkub Babatunde Mutalub , Monsurat Abdulwahab , Aida Hanum Ghulam Rasool , Sagir Mustapha , Siti Qusyasyiah Ahmad Suhaimi , Siti Safiah Mokhtar

Obesity is a complex metabolic disorder driven by an imbalance between energy intake and expenditure. A critical pathogenetic component of obesity is dysregulated hunger and satiety mechanisms, driven by both central and peripheral factors. This review explores the pathophysiology of obesity-induced hunger, focusing on key mechanisms involving neurohormonal signals, gut-brain communication, and the dysregulation of appetite-related pathways. It discusses the roles of hormones such as ghrelin, leptin, and insulin, as well as the influence of inflammatory processes on hunger regulation. Additionally, environmental and psychological factors contributing to food cravings and reward-driven eating are considered. The article also examines current and emerging therapeutic interventions targeting hunger and appetite control, including pharmacologic treatments, such as glucagon-like peptide-1 (GLP-1) receptor agonists, lifestyle modifications, and bariatric surgery. Novel strategies under investigation, including appetite-regulating peptides, are highlighted. Bridging the understanding of the intricate mechanisms driving obesity-related hunger with therapeutic advances provides a comprehensive framework for more effective treatment strategies to combat obesity and its associated comorbidities which will ultimately improve patient outcomes.

{"title":"Obesity-driven hunger: From pathophysiology to intervention","authors":"Ahmad Khusairi Azemi , Yahkub Babatunde Mutalub , Monsurat Abdulwahab , Aida Hanum Ghulam Rasool , Sagir Mustapha , Siti Qusyasyiah Ahmad Suhaimi , Siti Safiah Mokhtar","doi":"10.1016/j.obmed.2025.100588","DOIUrl":"10.1016/j.obmed.2025.100588","url":null,"abstract":"<div><div>Obesity is a complex metabolic disorder driven by an imbalance between energy intake and expenditure. A critical pathogenetic component of obesity is dysregulated hunger and satiety mechanisms, driven by both central and peripheral factors. This review explores the pathophysiology of obesity-induced hunger, focusing on key mechanisms involving neurohormonal signals, gut-brain communication, and the dysregulation of appetite-related pathways. It discusses the roles of hormones such as ghrelin, leptin, and insulin, as well as the influence of inflammatory processes on hunger regulation. Additionally, environmental and psychological factors contributing to food cravings and reward-driven eating are considered. The article also examines current and emerging therapeutic interventions targeting hunger and appetite control, including pharmacologic treatments, such as glucagon-like peptide-1 (GLP-1) receptor agonists, lifestyle modifications, and bariatric surgery. Novel strategies under investigation, including appetite-regulating peptides, are highlighted. Bridging the understanding of the intricate mechanisms driving obesity-related hunger with therapeutic advances provides a comprehensive framework for more effective treatment strategies to combat obesity and its associated comorbidities which will ultimately improve patient outcomes.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100588"},"PeriodicalIF":0.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143349496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of simple and specialized non-invasive tools in predicting of metabolic dysfunction-associated fatty liver disease severity and prognosis

Q2 Medicine

Obesity Medicine

Pub Date : 2025-01-25 DOI: 10.1016/j.obmed.2025.100582

Marjan Mokhtare , Shahin Sharafeh , Mohammadjavad Sotoudeheian , Amir M. Sadeghian , Said A. Al-Busafi

Objectives

Metabolic-associated fatty liver disease (MAFLD) is a universal health concern. Detecting advanced fibrosis significantly impacts prognosis. This study designated to assess the accuracy of FIB-4, FIB-6, Agile3+, Agile4, and NAFLD fibrosis score (NFS) in predicting disease severity.

Design and Methods

Clinical, laboratory, and FibroScan findings of adult MAFLD patients were recorded. A fibrosis (F) score over 10 kPa indicates advanced fibrosis. We assessed the area under the receiver operating characteristic curve (AUROCC), along with the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy with various cutoff values. Reliability was analyzed with the intra-class correlation coefficient (ICC).

Results

Advanced fibrosis was found in 5 of 103 patients (4.85%). AUROCC values were as follows: 0.967 for Agile3+, 0.951 for FIB-6, 0.932 for NFS, 0.909 for Agile4, and 0.869 for FIB-4. The PPVs ranged from 18.18% (FIB-4) to 57.09% (NFS), followed by 75.02% (FIB-6), and 18.18% (Agile4) to 100% (Agile3+). All tools achieved acceptable NPVs above 96%. The ICC between the fibrosis score and other tools was 0.772 (95% CI: 0.696-0.834). Significant differences were noted in gamma-glutamyl transferase (p=0.039), diabetes mellitus (P=0.011), platelet count, hemoglobin A1C, alkaline phosphatase, triglycerides, fasting blood glucose, and Vitamin D levels

{"title":"The role of simple and specialized non-invasive tools in predicting of metabolic dysfunction-associated fatty liver disease severity and prognosis","authors":"Marjan Mokhtare , Shahin Sharafeh , Mohammadjavad Sotoudeheian , Amir M. Sadeghian , Said A. Al-Busafi","doi":"10.1016/j.obmed.2025.100582","DOIUrl":"10.1016/j.obmed.2025.100582","url":null,"abstract":"<div><h3>Objectives</h3><div>Metabolic-associated fatty liver disease (MAFLD) is a universal health concern. Detecting advanced fibrosis significantly impacts prognosis. This study designated to assess the accuracy of FIB-4, FIB-6, Agile3+, Agile4, and NAFLD fibrosis score (NFS) in predicting disease severity.</div></div><div><h3>Design and Methods</h3><div>Clinical, laboratory, and FibroScan findings of adult MAFLD patients were recorded. A fibrosis (F) score over 10 kPa indicates advanced fibrosis. We assessed the area under the receiver operating characteristic curve (AUROCC), along with the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy with various cutoff values. Reliability was analyzed with the intra-class correlation coefficient (ICC).</div></div><div><h3>Results</h3><div>Advanced fibrosis was found in 5 of 103 patients (4.85%). AUROCC values were as follows: 0.967 for Agile3+, 0.951 for FIB-6, 0.932 for NFS, 0.909 for Agile4, and 0.869 for FIB-4. The PPVs ranged from 18.18% (FIB-4) to 57.09% (NFS), followed by 75.02% (FIB-6), and 18.18% (Agile4) to 100% (Agile3+). All tools achieved acceptable NPVs above 96%. The ICC between the fibrosis score and other tools was 0.772 (95% CI: 0.696-0.834). Significant differences were noted in gamma-glutamyl transferase (p=0.039), diabetes mellitus (P=0.011), platelet count, hemoglobin A1C, alkaline phosphatase, triglycerides, fasting blood glucose, and Vitamin D levels</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100582"},"PeriodicalIF":0.0,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Obesity Medicine

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀